Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial)

@inproceedings{Eckes2011KineticTO,
  title={Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial)},
  author={J{\"u}rgen Eckes and Oliver Schmah and Jan Willem Siebers and Ursula Groh and Stefan Zschiedrich and Beate Rautenberg and Annette Hasenburg and Martin Jansen and Martin Johannes Hug and Karl Winkler and Gerhard P{\"u}tz},
  booktitle={BMC Cancer},
  year={2011}
}
The therapeutic success of chemotherapeutic agents is often limited by severe adverse effects. To reduce toxicity of these drugs, nanoscale particle-based drug delivery systems (DDS) are used. DDS accumulate to some extent in tumor tissues, but only a very small portion of a given dose reaches this target. Accumulation of DDS in tumor tissues is supposed to be much faster than in certain other tissues in which side effects occur ("Kinetic Targeting"). Once saturation in tumor tissue is achieved… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
11 Citations
35 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 35 references

TM: Multiple Injections of Pegylated Liposomal Doxorubicin: Pharmakokinetics and Therapeutic Activity

  • Charrois GJR, Allen
  • J Pharmacol Exp Ther
  • 2003
Highly Influential
14 Excerpts

Similar Papers

Loading similar papers…